Opinion|Videos|October 21, 2024
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Key Takeaways
- CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety.
- Routes of administration vary, with some trials using intravenous delivery and others exploring intravesical administration to optimize therapeutic outcomes.
Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you explain in detail which PD-1/PD-L1 inhibitors are being investigated in phase 3 trials for BCG-naive patients? [describe CREST, POTOMAC, KEYNOTE, ALBAN,] (PMID 38849286; DOI
10.1016/S0302-2838(24)01302-2 ) - How do the routes of administration and durations of therapy differ among the agents/trials?
Bedke 2023 Steinberg 2024
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
